Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
pfizer
5
×
san diego blog main
san diego top stories
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
biotech
clinical trials
san francisco blog main
san francisco top stories
akcea therapeutics
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
celgene
detroit blog main
detroit top stories
drugs
fda
genentech
indiana blog main
indiana top stories
inotersen
national
onpattro
patisiran
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
starboard value
tafamidis
texas blog main
texas top stories
wisconsin blog main
What
approved
5
×
drug
bio
fda
alnylam
companies
disease
merck
news
pfizer
roundup
adu
afternoon
ago
akcea
alnylam’s
amyloidosis
attr
available
battle
beats
bids
biogen
cancer
combo
complicated
dating
debilitating
depression
digital
dire
epidemic
fatty
frenzied
game
genetic
gets
good
group
growing
Language
Current search:
pfizer
×
approved
×
@xconomy.com
4 years ago
Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
